ATE509103T1 - Neurotrophe faktoren - Google Patents

Neurotrophe faktoren

Info

Publication number
ATE509103T1
ATE509103T1 AT07120461T AT07120461T ATE509103T1 AT E509103 T1 ATE509103 T1 AT E509103T1 AT 07120461 T AT07120461 T AT 07120461T AT 07120461 T AT07120461 T AT 07120461T AT E509103 T1 ATE509103 T1 AT E509103T1
Authority
AT
Austria
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
AT07120461T
Other languages
English (en)
Inventor
Dinah Wen Yee Sah
Teit E Johansen
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE509103T1 publication Critical patent/ATE509103T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT07120461T 2001-03-12 2002-03-12 Neurotrophe faktoren ATE509103T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
ATE509103T1 true ATE509103T1 (de) 2011-05-15

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07120461T ATE509103T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren
AT02706759T ATE378353T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02706759T ATE378353T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Country Status (15)

Country Link
US (1) US20020055467A1 (de)
EP (2) EP1930439B1 (de)
JP (2) JP3738008B2 (de)
CN (1) CN1268744C (de)
AT (2) ATE509103T1 (de)
AU (1) AU2002240943B2 (de)
CA (1) CA2440767C (de)
CY (1) CY1111750T1 (de)
DE (1) DE60223511T2 (de)
DK (2) DK1930439T3 (de)
ES (2) ES2296899T3 (de)
NZ (1) NZ528790A (de)
PT (2) PT1373503E (de)
SI (2) SI1373503T1 (de)
WO (1) WO2002072826A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
DE69933771T2 (de) * 1998-07-14 2007-09-13 Janssen Pharmaceutica N.V. Neurotrophischer wachstumsfaktor
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ES2374971T3 (es) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
EP1463530A4 (de) * 2001-12-19 2006-09-06 Lijun Wang Adeno-assoziierte virusvermittelte abgabe von gdnf an skelettmuskeln
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
DE602004028801D1 (de) * 2003-01-31 2010-10-07 Biogen Idec Inc Neublastin-mutanten
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
ES2342397T3 (es) 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
KR101215697B1 (ko) * 2004-08-19 2012-12-28 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
EP1937295A2 (de) * 2005-10-11 2008-07-02 NS Gene A/S Behandlung von retinopathien mit gfr3-agonisten
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
KR101886029B1 (ko) * 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
EP3793617A4 (de) * 2018-05-17 2021-09-29 Helixmith Co., Ltd Behandlung von neuropathischem schmerz im zusammenhang mit durch chemotherapie induzierter peripherer neuropathie
CA3220333A1 (en) 2021-05-18 2022-11-24 Musashino University Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
DE69736428T2 (de) 1996-05-08 2007-08-30 Biogen Idec Ma Inc., Cambridge RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
DK1185648T3 (da) * 1999-06-02 2007-07-30 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst

Also Published As

Publication number Publication date
AU2002240943B2 (en) 2007-05-10
DK1930439T3 (da) 2011-08-29
SI1373503T1 (sl) 2008-04-30
EP1930439A1 (de) 2008-06-11
US20020055467A1 (en) 2002-05-09
EP1373503A2 (de) 2004-01-02
SI1930439T1 (sl) 2011-09-30
WO2002072826A2 (en) 2002-09-19
ES2296899T3 (es) 2008-05-01
DK1373503T3 (da) 2008-03-25
DE60223511D1 (de) 2007-12-27
CN1268744C (zh) 2006-08-09
PT1930439E (pt) 2011-07-25
CN1509333A (zh) 2004-06-30
NZ528790A (en) 2004-06-25
AU2002240943A2 (en) 2002-09-24
CA2440767A1 (en) 2002-09-19
PT1373503E (pt) 2008-02-26
ATE378353T1 (de) 2007-11-15
CA2440767C (en) 2012-05-29
ES2366610T3 (es) 2011-10-21
WO2002072826A3 (en) 2003-04-10
DE60223511T2 (de) 2008-10-23
EP1373503B1 (de) 2007-11-14
JP3738008B2 (ja) 2006-01-25
JP2004531242A (ja) 2004-10-14
HK1120556A1 (en) 2009-04-03
EP1930439B1 (de) 2011-05-11
JP2005198656A (ja) 2005-07-28
CY1111750T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
ATE522609T1 (de) Neurotrophe faktoren
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
PT1015585E (pt) Homologos de ligandos de tie
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
CY2014038I1 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20054836L (no) Nogo-reseptorbindingsprotein
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
WO2007045019A3 (en) Polyoleosins
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE60200162D1 (de) Härtungszusammensetzung
EA200100110A1 (ru) Нейротрофические факторы
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
NO20033452D0 (no) Polynukleotid konstrukter for ökt lysin produksjon
WO2001021794A3 (en) Smad associating polypeptides
WO2003090514A8 (en) Adipocyte complement related protein zacrp14

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1930439

Country of ref document: EP